Chinese biotech firm Varnotech snaps $84m Series B funding
Vaccine developer Varnotech has secure 600 million yuan ($84 million) in a Series B funding round.
Stay updated with breaking news from Fontus Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vaccine developer Varnotech has secure 600 million yuan ($84 million) in a Series B funding round.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
The meager post-IPO performance of Arm, Instacart, and Klaviyo means that “the first half of 2024 is the new second half of 2023” for other IPO hopefuls, according to Renaissance Capital’s Matthew Kennedy.
Kaitai Capital was the other lead investor in the round.
Proteona is a precision medicine company offering single-cell biomarker discovery services to translational and clinical researchers.